In 1987, Eisai first began research in the field of oncology. To date, we have accumulated proprietary knowledge through numerous trials and errors, leading to the creation of anticancer agents such as eribulin (Halaven®) and lenvatinib (Lenvima®). Leveraging partnerships in addition to this proprietary knowledge, we are working to improve the efficiency of innovative creations and continue to work toward relieving the anxiety of cancer patients over health.

We have designated oncology as one of its key strategic areas based on Human Biology. We aim to create innovative new drugs with new target molecules and mechanisms of action to contribute to the cure of cancers, as well as cancer prevention.